In this randomized, double-blind, placebo-controlled Phase 1b study, multiple ascending doses of RGLS8429 or placebo will be administered via subcutaneous injection to subjects with ADPKD to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of RGLS8429.
Primary Objectives~To assess the safety and tolerability of RGLS8429~To assess the impact of RGLS8429 on ADPKD biomarkers~Secondary Objectives~To assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV)~To characterize the pharmacokinetic (PK) properties of RGLS8429~To assess the impact of RGLS8429 on renal function